Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 82 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Hydrochlorothiazide 25 mg Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg

NCT00649038
View directory record Official record
Conditions
Healthy
Interventions
Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg, Lotensin HCT® Tablets 20 mg/25 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Phase 4 Interventional Results available

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients

NCT00744237
View directory record Official record
Conditions
Hypertension, Type 2 Diabetes Mellitus
Interventions
Nebivolol, Metoprolol ER, HCTZ
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
62
States / cities
Athens, Alabama • Huntsville, Alabama • Bell Gardens, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2011 · Synced Oct 1, 2026, 4:42 PM EDT
Recruiting Phase 1 Interventional

Mitigating the Pro-inflammatory Phenotype of Obesity

NCT04934228
View directory record Official record
Conditions
Blood Pressure, Diabetes, Obesity, Insulin Resistance, Diuretics Drug Reactions, Sympathetic Nerve Activity
Interventions
Hydrochlorothiazide 12.5Mg Tab, Clonidine Pill, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma

NCT06205407
View directory record Official record
Conditions
Healthy Participants
Interventions
Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris, Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 1, 2026, 4:42 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Chlorthalidone and HCTZ Impacts on Platelet Activation

NCT02100462
View directory record Official record
Conditions
Hypertension
Interventions
Chlorthalidone 12.5 mg, Hydrochlorothiazide 25 mg, Aspirin 81 mg
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension

NCT00667719
View directory record Official record
Conditions
Essential Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 1, 2026, 4:42 PM EDT
Completed No phase listed Observational

ACE Inhibitors Combined With Exercise for Seniors - Pilot Study

NCT01891513
View directory record Official record
Conditions
Hypertension, Aging
Interventions
Exercise, ACE inhibitor + exercise, Thiazide diuretic + exercise, Angiotensin receptor blocker + exercise
Behavioral · Drug
Lead sponsor
University of Florida
Other
Eligibility
65 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg/25 mg Tablet Under Fasted Conditions

NCT01102478
View directory record Official record
Conditions
Hypertension
Interventions
losartan potassium / hydrochlorothiazide
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Phase 4 Interventional

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

NCT00240448
View directory record Official record
Conditions
Hypertension
Interventions
telmisartan 80 mg/hydrochlorothiazide 25 mg, valsartan 160 mg/hydrochlorothiazide 25 mg, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
100
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Phase 4 Interventional Results available

Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans

NCT00739596
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Not applicable Interventional Results available

Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease

NCT00865124
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Vascular Disease
Interventions
Spironolactone, Hydrochlorothiazide + potassium, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions

NCT00835042
View directory record Official record
Conditions
Healthy
Interventions
Moexipril HCl/hydrochlorothiazide 15/25 mg tablets, UNIRETIC® 15/25 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
2
States / cities
Saint Charles, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.

NCT00698646
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan + HCTZ, Valsartan, HCTZ
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
70 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Escondido, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 1, 2026, 4:42 PM EDT
Terminated Phase 3 Interventional Results available

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People

NCT01259297
View directory record Official record
Conditions
Cardiovascular Events
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo for Aliskiren, Placebo for Amlodipine, Placebo for Hydrochlorothiazide (HCTZ)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older
Enrollment
2,336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Northridge, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg

NCT01019590
View directory record Official record
Conditions
Healthy
Interventions
Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg, Benicar HCT ® Tablets 40 mg/25 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

NCT01692301
View directory record Official record
Conditions
Hypertension
Interventions
LCZ696, Olmesartan, LCZ696 matching placebo, Olmesartan matching placebo, amlodipine, hydrochlorothiazide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
11
States / cities
Clearwater, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg

NCT00648011
View directory record Official record
Conditions
Healthy
Interventions
Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg, Accuretic™ Tablets 20 mg/25 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Phase 4 Interventional Results available

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

NCT00403481
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil, Olmesartan medoxomil plus Hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
27
States / cities
Birmingham, Alabama • Mesa, Arizona • Searcy, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

NCT00765674
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Phase 3 Interventional

Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension

NCT00387517
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Phase 3 Interventional

Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension

NCT01415505
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Valsartan and Hydrochlorothiazide
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
135
States / cities
Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fasting Conditions

NCT00778726
View directory record Official record
Conditions
Healthy
Interventions
Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2008 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure

NCT00402103
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Oct 1, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients

NCT00459056
View directory record Official record
Conditions
Abdominal Obesity, Hypertension
Interventions
Carvedilol CR + Lisinopril, Lisinopril + HCTZ
Drug
Lead sponsor
St. Paul Heart Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2013 · Synced Oct 1, 2026, 4:42 PM EDT